Shortages threaten corporate profits, likely to end soon

We think the GLP1 shortage is going to end in the first half of 2025. Here's why.

Ozempic approved for Chronic Kidney Disease

The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.

Tradjenta: An alternative to GLP1 for Type 2 Diabetes

We take a look at one of the alternatives to GLP1s that has been on the market a long time -- Tradjenta.

GLP1 use by younger people

We dig into the reports of younger people using GLP1s like Ozempic, Wegovy and others.

Novo's Amycretin delivers great Phase 2 results

Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.

The battle for compounded GLP1 continues

The battle for compounded GLP1s rages on -- powerful organizations with profit incentives continue to push for compounded GLP1s, with consumers caught in the middle.

Government Price negotiations on Ozempic and Wegovy

The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?

Pancreatitis and Gallstones after massive weight loss

We look into pancreatitis and gallstones issues that caused one death and more hospitalizations, caused at least in part by GLP1s

What's the best injection site for GLP1s?

What's the best site for injecting Ozempic, Wegovy, Mounjaro, or Zepbound? We check anecdata, manufacturers, and 3rd parties.

Zepbound coverage for Sleep Apnea gets Agency approval

Center for Medicare and Medicaid declared that Zepbound is covered by insurance for treating Sleep Apnea, given it's effectiveness.

Robert F. Kennedy Jr vs GLP1

RFK Jr.'s appointment and it's effect on GLP1s. Is it truly anti-GLP1? Or a case of tactics?

Research suggesting GLP1 is a brain drug

Why has modern scientific opinion shifted to GLP1 being a brain drug rather than a gut drug? We dive into the critical research paper supporting the shift.